Project Description

ESKAPE pathogens is alarming. Within which, the Class D OXA (Oxacillinase) type β-Lactamases that belong to ESBL group and carbapenemases group is a significant threat due to the lack of active inhibitors to circumvent these enzymes in the clinical setting. This includes ESBL OXA’s such as OXA-1, OXA-10 are seen in E.coli and P.aeuruginosa, and carbapenemases OXA’s such as OXA-48 like and OXA-23/24/51/58 like in Klebsiella spp and A. baumannii respectively. Such OXA producers pose a significant challenge for management, with very few options like colistin and tigecycline available, however these two drugs doesn’t achieve effective serum level and poor safety profile for severe lower respiratory infections, these drugs are no more recommended. Subsequently, these will be tested in-vitro for its efficacy against a wide range of OXA specific variants produced in the clinical isolates. The multidisciplinary approach with computational screening, chemical synthesis, and in-vitro evidence will identify a novel therapeutic compound for XDR pathogens.